×
Ardelyx Operating Expenses 2013-2024 | ARDX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Ardelyx operating expenses from 2013 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.
View More
Ardelyx Operating Expenses 2013-2024 | ARDX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Ardelyx operating expenses from 2013 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.
Related Stocks
Company Name
Market
Cap
Zoetis (ZTS)
$88.7B
Takeda Pharmaceutical (TAK)
$47.3B
Merck (MKGAF)
$23.7B
Astellas Pharma (ALPMY)
$21.5B
Summit Therapeutics (SMMT)
$19B
Sandoz Group AG (SDZNY)
$17.5B
United Therapeutics (UTHR)
$15.4B
Shionogi (SGIOY)
$13.3B
Neurocrine Biosciences (NBIX)
$12.4B
Catalent (CTLT)
$11B
Orion OYJ (ORINY)
$7.4B
Revolution Medicines (RVMD)
$7.3B
Jazz Pharmaceuticals (JAZZ)
$6.9B
Ionis Pharmaceuticals (IONS)
$6.1B
Hikma Pharmaceuticals Plc (HKMPF)
$5.7B
Madrigal Pharmaceuticals (MDGL)
$5.1B
Crinetics Pharmaceuticals (CRNX)
$4.2B
Corcept Therapeutics (CORT)
$4.1B
Dyne Therapeutics (DYN)
$3.5B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.7B
PTC Therapeutics (PTCT)
$2.7B
Arrowhead Pharmaceuticals (ARWR)
$2.5B
Catalyst Pharmaceuticals (CPRX)
$2.4B
Soleno Therapeutics (SLNO)
$2.1B
Recursion Pharmaceuticals (RXRX)
$1.9B
Centessa Pharmaceuticals (CNTA)
$1.8B
Xencor (XNCR)
$1.6B
BioCryst Pharmaceuticals (BCRX)
$1.6B
Harrow (HROW)
$1.5B
Cassava Sciences (SAVA)
$1.5B